New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, November 13, 2026

Back to the front page

The Spy Who Shagged The Market

Nvidia’s leadership scandal puts its AI-market role under scrutiny, with comparisons to AIG’s pre-GFC liquidity influence.

AIG $43B
WHAT ARE WE DOING? “Contrarians At The Gate” 1 click

From X

@InvestSpecial

Dalius - Special Sits on X

A surprising development at $RGS Five of its six directors failed to secure majority support at the Oct 28 annual meeting, with Bill Charters being the only exception. Shareholders also rejected the executive compensation proposal. As a reminder, Bill Charters is the founder of Sabal Capital Management, a fund focused on special situations and restructurings. He was part of the 2024 activist group, joined the board in April 2026 and currently owns ~4% of RGS. There had been nothing to suggest he was pushing for another board shakeup. The five directors have now offered their resignations, but with no alternative slate on the table, the board itself will decide whether to accept them or keep everyone in place. Andrew Alfano, one of the five, was appointed chairman just one day after the vote, which suggests they are staying put. Alfano has said he will speak with shareholders to understand what prompted the vote, so we may get more clarity soon. My suspicion is that investors are becoming increasingly skeptical about the prospects of refinancing the debt, especially as the process keeps dragging on. Any thoughts here?
@convequity

Convequity on X

I think some bears underestimate $PLTR's model expertise. We have argued that Palantir had more model expertise than it had shown publicly, and that lacking its own foundation model did not put it at the competitive disadvantage those bears assumed. The earlier NVIDIA partnership, which included NeMo Retriever and Nemotron, was my first clue. I see the public Nemotron results as evidence of that expertise. These results fit our argument and were what I expected. Palantir's slide on McCarthy's construction requests for information shows a tuned Nemotron model outperforming Sonnet and Astra on classification. FourWeekMBA reads the chart, which has no data labels, as approximately 73% balanced accuracy for tuned Nemotron, approximately 66% for Sonnet and approximately 62% for Astra. On a cost basis the slide leaves unexplained, FourWeekMBA places Nemotron at approximately $0.10 per million tokens. The slide leaves open whether that includes hosting, tuning and Palantir's software fees. I would want the full customer cost comparison to judge the savings. I still regard Nemotron as a weak starting model. If Western developers make state-of-the-art open-source models available, I expect Palantir to use customer data, task-specific benchmarks and tuning to deliver further improvements in performance and cost. That could make Palantir economical for smaller enterprises as well as very large ones. Savings on model usage could cover Palantir's software premium if customers can move enough work to cheaper tuned models while maintaining the quality they need. As customers spend more on tokens relative to software, the potential savings grow. I expect Palantir's model expertise to become more valuable because it could reduce a larger part of the customer's total bill.

Investor Letters

All letters

Qualcomm Custom ASICs?

Qualcomm’s Alphawave SerDes, CPU cores and HBC could support custom AI ASICs as hyperscalers build heterogeneous fleets beyond GPUs.

QCOM $190B
Chipstrat 2 clicks

QXO Inc Earnings Update: Q3 2026

QXO's Q3 sales rose 79% to $4.9 billion after TopBuild and Kodiak acquisitions, while acquisition debt lifted interest expense to $163…

QXO $13B
SixSigmaCapital: Navigating the Financial Markets 2 clicks

IEH Corporation: Research Note

IEH Corporation posted Q2 revenue growth of 51% to $10.7 million and a record $56 million backlog, led by defense and medical demand.

IEHC $78M
Atrium Research - Equity Research 1 click

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

QURE $1.7B
Triple S Special Situations Investing 2 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 88 of 290

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.